Biotech | August 12, 2025
Sartorius and Nanotein Technologies partner to advance cell therapy manufacturing
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
This certification validates the plant’s robust capabilities in manufacturing a wide range of sterile dosage forms
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Commercial production is expected to begin soon
Subscribe To Our Newsletter & Stay Updated
